CORE--HYBRIDOMA FACILITY

Hybrid Core是一个有12年历史的工厂，已经生产了350多个 克隆抗体 在过去的糖尿病中心资助周期中， 核心小组为16名中心研究人员生产了抗体， 免疫接种，并提供储存和腹水生产服务， 一百五十次。 本供资周期内增加的专门服务 包括体外免疫和人单克隆抗体的产生 抗体，以满足中心研究者的独特要求。 下一个供资周期的Hybrid Core目标包括： 为客户提供更全面、更先进的服务， 中心 这包括集成几乎所有的步骤， 单克隆抗体进入实验室设施。 它包括 开发免疫原，支持筛选免疫测定， 杂交瘤上清液、亚克隆、冷冻保存和腹水 生产 此外，技术进步应该允许更多的 高效开发人单克隆抗体。 教育和 将增加技术支助， 由不熟悉免疫学技术的研究者进行取芯。 还正在开展发展项目， 实验室的专业知识。 涉及分子技术的研究， 改变单克隆抗体的同种型已经开始。 重组抗体的进一步工作将完成，尽管这种类型的抗体将在未来几年内被发现。 服务将不会提供，直到技术使其 性能更加可行。 替代技术，例如 将支持在鸡中生产单克隆抗体， 示范项目，直到他们证明纳入核心的 服务 一个专家咨询委员会将协助作出决定 关于这些技术的实用性。 通过这些举措，Hybrid Core将继续保持领先地位。 前沿的抗体技术，提供优良的服务和培训 糖尿病中心研究人员的咨询。

The Hybridoma Core is a 12 year old facility that has produced over 350 monoclonal antibodies. During the past Diabetes Center funding cycle, the Core produced antibodies for 16 Center investigators, performed 54 immunizations and provided storage and ascites production services over 150 times. Specialized services added during the present funding cycle included in vitro immunizations and production of human monoclonal antibodies to satisfy the unique requirements of Center investigators. Goals for the Hybridoma Core in the next funding cycle involve providing more complete and technically advanced services for the Center. This includes integrating almost all of the steps in making monoclonal antibodies into the laboratory facility. It includes development of immunogens, support for screening immunoassays for hybridoma supernatants, subcloning, cryopreservation and ascites production. In addition, technical advancements should allow more efficient development of human monoclonal antibodies. Educational and technical support will be increased to provide greater access to the Core by investigators not skilled in immunologic techniques. Developmental projects are also being undertaken to advance the laboratory's expertise. Studies involving molecular techniques to alter the isotype of monoclonal antibodies have already been initiated. Further work in recombinant antibodies will be done, although this type of service will not be offered until the technology makes its performance more feasible. Alternative techniques, such as the production of monoclonal antibodies in chickens, will be supported as demonstration projects until they justify inclusion into the Core's services. An expert Advisory Committee will aid in decisions concerning the utility of these techniques. Through these initiatives the Hybridoma Core will remain on the cutting edge of antibody technology and provide excellent service, and training and consultation for Diabetes Center investigators.